Ethinylestradiol/norgestimate oral

Drug Profile

Ethinylestradiol/norgestimate oral

Alternative Names: Norgestimate/ethinyl estradiol; Ortho Tri-Cyclen; Ortho Tri-Cyclen Lo; Ortho-Prefest; Prefest

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development; Ortho-McNeil Pharmaceutical
  • Developer Janssen Research & Development; Ortho-McNeil Pharmaceutical
  • Class Alkylated estrogenic steroids; Oral contraceptives
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Pregnancy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pregnancy (Prevention) (In volunteers) in Netherlands (PO, Tablet)
  • 01 Sep 2014 Janssen Research & Development completes a phase I trial in Contraception (In volunteers) in Netherlands (NCT02127593)
  • 13 May 2014 Janssen Research & Development plan a phase I bioequivalence trial in healthy women in Netherlands (NCT02127593)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top